IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.
Original languageEnglish
JournalOral Oncology
Volume86
Pages (from-to)91-99
Number of pages9
ISSN1368-8375
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • Cancer stem cells
  • Head and neck cancer
  • HPV
  • Hypoxia
  • p16
  • Personalized medicine
  • Radiogenomics
  • Radiotherapy
  • SNP

Fingerprint

Dive into the research topics of 'IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer'. Together they form a unique fingerprint.

Cite this